Trial intelligence / Profile preview

Peritoneal carcinomatosis from gastric cancer treated with neoadjuvant systemic plus intraperitoneal chemotherapy, cytoreductive surgery, and intraoperative hyperthermic intraperitoneal chemotherapy

2009-011162-29Phase 2Active

Sponsor
Fundación Investigación Biomédica Hospital General Universitario Gregorio Marañón
Start
Mar 2009
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, open-label, single-arm trial of docetaxel, cisplatin, fluorouracil, carboplatin, methotrexate and 1 more in peritoneal carcinomatosis (PC), sponsored by Fundación Investigación Biomédica Hospital General Universitario Gregorio Marañón. Primary endpoints: Disease-free survival and Overall survival. Started Mar 2009; status: active.

02

Drugs

docetaxelcisplatinfluorouracilcarboplatinmethotrexate
03

Conditions

peritoneal carcinomatosis (PC)

Beyond the preview

Go deeper on 2009-011162-29.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2009-011162-29.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call